SAN
DIEGO, Nov. 8, 2023 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (Nasdaq: NBIX) today announced the
availability of DISCOVER TD™, an interactive digital tool
designed to help healthcare providers learn about and identify
tardive dyskinesia.
Built in collaboration with clinical experts and Level Ex, "the
world's leading medical video game studio," DISCOVER TD uses
gameplay, artistry, and cutting-edge technology to bring patient
visits to life in realistic detail. Each avatar presents various
manifestations of tardive dyskinesia (TD) or other drug-induced
movement disorders and is complete with a unique patient history.
Users can pose questions, screen, diagnose and determine
appropriate management plans by interacting with virtual
patients.
DISCOVER TD, which was recently named the PM360
Trailblazer Award 2023 Gold Winner, can be accessed at
https://mind-td.com/discover-td for healthcare providers to
use any time from any device with Internet access. It can also be
used to train students and residents.
"An interactive tool can help healthcare providers who may be
less experienced in diagnosing and managing TD practice patient
interactions to help identify the condition," said Mercedes Perez-Rodriguez, M.D., Ph.D., Associate
Professor of Psychiatry and Associate Training Director for
Research at the Icahn School of Medicine at Mount Sinai. "In
addition to the patient history, the key to differential diagnosis
is knowing what the characteristic movements of different
drug-induced movement disorders look like, and this tool helps
users distinguish these movements through a simulated physical exam
so that they can make a proper diagnosis and management plan."
"TD can be a significant burden for patients already managing an
underlying mental illness," said Eiry W. Roberts, M.D., Chief
Medical Officer at Neurocrine Biosciences. "It's our hope that this
new educational tool will further empower healthcare professionals
to confidently recognize, diagnose and appropriately manage TD,
which can have a positive impact for patients."
The tool will be available for demonstration at the Neurocrine
Medical booth at the 2023 NEI Congress, November 9–12 in
Colorado Springs, Colo.
View more information about DISCOVER TD at
https://vimeo.com/levelex/discovertd.
Dr. Mercedes Perez-Rodriguez is a
paid consultant for Neurocrine Biosciences, Inc.
About Tardive Dyskinesia (TD)
Tardive dyskinesia (TD)
is a movement disorder that is characterized by uncontrollable,
abnormal and repetitive movements of the face, torso and/or other
body parts, which may be disruptive and negatively impact patients.
The condition is associated with taking certain kinds of mental
health medicines (like antipsychotics) that help control dopamine
receptors in the brain. Taking antipsychotics commonly prescribed
to treat mental illnesses such as major depressive disorder,
bipolar disorder, schizophrenia and schizoaffective disorder, and
other prescription medicines (metoclopramide and prochlorperazine)
used to treat gastrointestinal disorders are associated with TD. In
patients with TD, these treatments are thought to result in
irregular dopamine signaling in a region of the brain that controls
movement. The symptoms of TD can be severe and are often persistent
and irreversible. TD is estimated to affect approximately 600,000
people in the United States.
About Neurocrine Biosciences
Neurocrine
Biosciences is a leading neuroscience-focused, biopharmaceutical
company with a simple purpose: to relieve suffering for people with
great needs, but few options. We are dedicated to discovering and
developing life-changing treatments for patients with
under-addressed neurological, neuroendocrine, and neuropsychiatric
disorders. The company's diverse portfolio includes FDA-approved
treatments for tardive dyskinesia, chorea associated with
Huntington's disease, Parkinson's disease, endometriosis* and
uterine fibroids*, as well as a robust pipeline including multiple
compounds in mid- to late-phase clinical development across our
core therapeutic areas. For three decades, we have applied our
unique insight into neuroscience and the interconnections between
brain and body systems to treat complex conditions. We relentlessly
pursue medicines to ease the burden of debilitating diseases and
disorders, because you deserve brave science. For more information,
visit neurocrine.com, and follow the company on LinkedIn, X
(formerly Twitter) and Facebook. (*in collaboration with
AbbVie)
NEUROCRINE BIOSCIENCES, NEUROCRINE and YOU DESERVE BRAVE SCIENCE
are registered trademarks of Neurocrine Biosciences, Inc. The
Neurocrine logo and DISCOVER TD are trademarks of Neurocrine
Biosciences, Inc.
Forward-Looking Statements
In addition to historical
facts, this press release contains forward-looking statements that
involve a number of risks and uncertainties. These statements
include, but are not limited to, statements regarding the Company's
plans to advance a tool that may help address the needs of people
living with TD, and the value that such a tool may bring to
patients. Among the factors that could cause actual results to
differ materially from those indicated in the forward-looking
statements are: whether the Company can successfully advance a tool
that may help address the unmet needs of people living with TD;
risks and uncertainties associated with the commercialization of
the Company's products; risks that the Company's products may be
precluded from commercialization by the proprietary rights of third
parties, or have unintended side effects or adverse reactions;
risks and uncertainties relating to competitive products and
technological changes that may limit demand for the Company's
products; risks associated with our dependence on third parties for
development and manufacturing activities related to the Company's
products, and our ability to manage these third parties; risks that
the FDA or other regulatory authorities may make adverse decisions
regarding our products; risks associated with potential generic
entrants for our products; and other risks described in the
Company's periodic reports filed with the Securities and
Exchange Commission, including without limitation the Company's
quarterly report on Form 10-Q for the quarter ended September
30, 2023. Neurocrine Biosciences disclaims any obligation to
update the statements contained in this press release after the
date hereof.
©2023 Neurocrine Biosciences, Inc. All Rights Reserved.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-launches-interactive-digital-tool-for-use-by-healthcare-providers-to-help-expand-education-on-identifying-and-diagnosing-tardive-dyskinesia-301981920.html
SOURCE Neurocrine Biosciences, Inc.